Introduction and Objective: Basal bolus insulin (BBI) therapy is associated with body weight (BW) gain and an increased risk of hypoglycemia, further increasing the treatment burden for people with T2D. This real-world study assessed the efficacy and safety of switching from BBI to iGlarLixi, a once-daily fixed-ratio combination of insulin glargine 100 U/mL plus lixisenatide, in people with T2D.

Methods: This real-world retrospective study included people with T2D (≥18 years) who received ≥1 iGlarLixi prescription during the identification (ID) period following prior treatment with BBI using the Optum Market Clarity® electronic medical record dataset of people with T2D from the United States. The primary endpoint was HbA1c change at 6 months. Secondary endpoints were HbA1c change at 3 months, BW change and hypoglycemic event rate at 6 months.

Results: In total, 11,887 people received ≥1 iGlarLixi prescription during the ID period, and of these, 372 had switched from a BBI regimen to iGlarLixi (mean age, 59 years; mean baseline HbA1c, 9.55%; mean baseline BW, 101.9 kg). From baseline to Month 6, switching to iGlarLixi resulted in a significant mean HbA1c reduction of −0.93% (95% confidence interval [CI]: −1.13, −0.74; p<0.0001) to 8.61% (n=372). At Month 3, HbA1c was 8.68% (n=204). The mean change in BW at 6 months was −0.89 kg (95% CI: −1.61, −0.18; n=359). The hypoglycemia event rate was 46.24 per 100 person-years of follow-up (P100PYFU) at baseline and 40.32 P100PYFU (event rate ratio: 0.77; 95% CI: 0.57, 1.05) after 6 months of iGlarLixi treatment.

Conclusion: In a real-world setting, people with T2D and elevated HbA1c switching from a BBI regimen to a once-daily injection of iGlarLixi achieved lower HbA1c, weight benefit and numerically lower hypoglycemic events.

Disclosure

F. Giorgino: Consultant; AstraZeneca, Boehringer-Ingelheim, Eli Lilly and Company, LifeScan Diabetes Institute, Merck Sharp & Dohme Corp., Medtronic, Novo Nordisk, Roche Diabetes Care, Sanofi. Research Support; Eli Lilly and Company, Roche Diabetes Care. F. Lauand: Employee; Sanofi. Stock/Shareholder; Sanofi. S. Servera: Employee; Sanofi. X. Li: Employee; Sanofi. Z. Taybani: Advisory Panel; Boehringer-Ingelheim. Consultant; Novo Nordisk, AstraZeneca. Speaker's Bureau; Sanofi. A.Y.Y. Cheng: Advisory Panel; Abbott. Speaker's Bureau; Amgen Inc., AstraZeneca, Bausch Health. Advisory Panel; Bayer Inc. Speaker's Bureau; Abbott, Bayer Inc. Research Support; Applied Therapeutics Inc. Advisory Panel; Boehringer-Ingelheim. Speaker's Bureau; Boehringer-Ingelheim, Dexcom, Inc. Advisory Panel; Dexcom, Inc., Eli Lilly and Company. Speaker's Bureau; Eli Lilly and Company. Advisory Panel; Eisai Inc. Speaker's Bureau; GlaxoSmithKline plc. Advisory Panel; HLS Therapeutics Inc. Speaker's Bureau; HLS Therapeutics Inc., Insulet Corporation. Advisory Panel; Insulet Corporation, Janssen Pharmaceuticals, Inc. Speaker's Bureau; Janssen Pharmaceuticals, Inc., Medtronic. Advisory Panel; Novo Nordisk. Speaker's Bureau; Novo Nordisk. Research Support; Novo Nordisk. Speaker's Bureau; Pfizer Inc. Advisory Panel; Sanofi. Speaker's Bureau; Sanofi. Research Support; Sanofi. Advisory Panel; Takeda Canada, AstraZeneca, Sanofi. Consultant; Abbott, AstraZeneca, Bayer Inc., Boehringer-Ingelheim, Dexcom, Inc., Eisai Inc., Eli Lilly and Company, Insulet Corporation, HLS Therapeutics Inc., Janssen Pharmaceuticals, Inc., Novo Nordisk, Sanofi, Takeda Pharmaceutical Company Limited. V. Fonseca: Consultant; Abbott, Bayer Inc. Stock/Shareholder; BRAVO4HEALTH, LLC. Consultant; Corcept Therapeutics. Speaker's Bureau; Eli Lilly and Company. Research Support; Fractyl Health, Inc. Consultant; Sun Pharmaceutical Industries Ltd. Stock/Shareholder; Amgen Inc. A. Tebaibia: None. I. Anaforoglu: None.

Funding

Sanofi

© 2024 by the American Diabetes Association
2024
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.